Daktari Diagnostics, a Cambridge, MA-based developer of an HIV diagnostics system for use in developing countries, has wrapped up $1.8 million in equity-based funding from 32 unnamed investors, according to an SEC filing. The firm has previously raised about $3.7 million, from a number individual investors, Hub Angels, Launchpad Venture Group, Mass Medical Angels, Norwich Ventures, Partners Innovation Fund, and has also attracted money from The Bill & Melinda Gates Foundation. Daktari is working on a device for testing blood in locations that lack traditional lab settings, and has serial biotech entrepreneur Stanley Lapidus and MIT Sloan School of Management professor Ed Roberts as members of its board of directors.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
